Pulmonary Embolism Symposium (PERT 2017)

 

Pulmonary Embolism Symposium (PERT 2017)

Current Regulatory Environment and Potential FDA Role in Furthering the Goals of the PERT Consortium to Improve Outcomes for Patients with PE and VTE

By Pulmonary Embolism Symposium (PERT 2017)
By Pulmonary Embolism Symposium (PERT 2017)
0 views
October 16, 2017
Comments 0
Login to view comments. Click here to Login
Session 4: Anticoagulation
11:14
Pulmonary Embolism Symposium (PERT 2017)

Current Regulatory Environment and Potential FDA Role in Furthering …

11:46
Pulmonary Embolism Symposium (PERT 2017)

DOACs and Other Heparin Alternatives

Feat. R. Rosovsky
13:55
Pulmonary Embolism Symposium (PERT 2017)

NOAC Reversal Agents - Our Early Experience

Feat. G. Davis
10:12
Pulmonary Embolism Symposium (PERT 2017)

Long Term Anticoagulation - How and For How Long?

10:05
Pulmonary Embolism Symposium (PERT 2017)

Panel Discussion - Q&A with the Experts from PERT 2017